Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from Firebrick Pharma Limited ( (AU:FRE) ).
Firebrick Pharma Limited has disclosed a change in the indirect shareholding of director Peter Laurence Molloy, as required under ASX listing rules. The notice states that Molloy’s relevant interest is held through his associate, Christine Louise Molloy, and entities linked to her.
According to the filing, Christine Louise Molloy acquired 245,000 ordinary fully paid shares in Firebrick Pharma via an on-market trade valued at $9,856.02. Following this transaction, the total indirect holdings associated with the director increased, signalling a modest vote of confidence in the company by its leadership but without indicating any broader strategic shift or corporate action.
More about Firebrick Pharma Limited
Firebrick Pharma Limited is an Australian pharmaceutical company focused on developing and commercialising healthcare products. The company operates in the broader life sciences sector, with its activities centred on drug development and related medical solutions for domestic and potentially international markets.
Average Trading Volume: 187,797
Technical Sentiment Signal: Sell
Current Market Cap: A$11.39M
For a thorough assessment of FRE stock, go to TipRanks’ Stock Analysis page.